The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of center case volume on cardiotoxicity during adjuvant trastuzumab in breast cancer.
Nicolas J. Chin-Yee
No relevant relationships to disclose
Andrew Yan
Honoraria - Roche
George A. Tomlinson
No relevant relationships to disclose
Craig Earle
No relevant relationships to disclose
Maureen E. Trudeau
Honoraria - Roche
Research Funding - Roche
Murray Krahn
No relevant relationships to disclose
Dennis Ko
No relevant relationships to disclose
Monika Krzyzanowska
No relevant relationships to disclose
Raveen Pal
No relevant relationships to disclose
Christine B. Brezden
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Kelvin K. Chan
No relevant relationships to disclose